206 results on '"Bonni, Azad"'
Search Results
2. The anaphase-promoting complex controls a ubiquitination-phosphoprotein axis in chromatin during neurodevelopment.
3. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
4. PHF6-mediated transcriptional control of NSC via Ephrin receptors is impaired in the intellectual disability syndrome BFLS
5. APC7 mediates ubiquitin signaling in constitutive heterochromatin in the developing mammalian brain
6. MeCP2 represses the activity of topoisomerase IIβ in long neuronal genes
7. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data
8. Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation
9. Sumoylated SnoN interacts with HDAC1 and p300/CBP to regulate EMT-associated phenotypes in mammary organoids
10. Epigenetic Regulation of the Cerebellum
11. Transcriptomic mapping uncovers Purkinje neuron plasticity driving learning
12. Epigenetic Regulation of the Cerebellum
13. Chromatin-Binding Protein PHF6 Regulates Activity-Dependent Transcriptional Networks to Promote Hunger Response
14. Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30.006)
15. PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial–mesenchymal transition
16. CHARGE syndrome protein CHD7 regulates epigenomic activation of enhancers in granule cell precursors and gyrification of the cerebellum
17. Altered neuronal physiology, development, and function associated with a common chromosome 15 duplication involving CHRNA7
18. Regulation of neuronal connectivity in the mammalian brain by chromatin remodeling
19. Chromatin Environment and Cellular Context Specify Compensatory Activity of Paralogous MEF2 Transcription Factors
20. Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice
21. Sensory experience remodels genome architecture in neural circuit to drive motor learning
22. The Hao-Fountain syndrome protein USP7 regulates neuronal connectivity in the brain via a novel p53-independent ubiquitin signaling pathway
23. Astrocyte deletion of α2-Na/K ATPase triggers episodic motor paralysis in mice via a metabolic pathway
24. Regulation of epithelial-mesenchymal transition and organoid morphogenesis by a novel TGFβ-TCF7L2 isoform-specific signaling pathway
25. The chromatin remodeling enzyme Chd4 regulates genome architecture in the mouse brain
26. Robust principal component analysis for accurate outlier sample detection in RNA-Seq data
27. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
28. Pathogenesis of Börjeson-Forssman-Lehmann syndrome: Insights from PHF6 function
29. Chromatin remodeling inactivates activity genes and regulates neural coding
30. Correction: PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial–mesenchymal transition
31. Epigenetic Regulation of the Cerebellum
32. Cellular and molecular characterization of multiplex autism in human induced pluripotent stem cell-derived neurons
33. Conditional knockout of UBC13 produces disturbances in gait and spontaneous locomotion and exploration in mice
34. Exploratory Delayed-Start Analysis Of PASADENA Part 3 52-Week OLE Evaluating Prasinezumab Efficacy On Motor Progression And Complications In Early-Stage PD (S32.005)
35. MeCP2 Represses the Activity of Topoisomerase IIβ in Long Neuronal Genes
36. Regulation of dendrite morphogenesis by extrinsic cues
37. A Cdh1-APC/FMRP Ubiquitin Signaling Link Drives mGluR-Dependent Synaptic Plasticity in the Mammalian Brain
38. This is NOT the End for Immunotherapy in Parkinson’s Disease – A Perspective from Early Drug Development Scientists
39. List of Contributors
40. Non-cell Autonomous Degeneration
41. Sumoylated SnoN interacts with HDAC1 and p300/CBP to regulate EMT in mammary organoids
42. Trial of Prasinezumab in Early-Stage Parkinson’s Disease
43. Publisher Correction: Sensory experience remodels genome architecture in neural circuit to drive motor learning
44. Angelman syndrome patient neuron screen identifies a potent and selective clinical ASO targeting UBE3A-ATS with long lasting effect in cynomolgus monkey
45. A 104-week delayed-start analysis of PASADENA (Phase II study evaluating the safety and efficacy of prasinezumab in early Parkinson’s disease) (S16.008)
46. Trial of Prasinezumab in Early-Stage Parkinson's Disease
47. Targeted Atp1a2 knockdown by antisense oligonucleotides leads to reduced SOD1 aggregation and accelerated disease progression in the SOD1*G93A mouse model of ALS
48. Additional file 14 of Altered neuronal physiology, development, and function associated with a common chromosome 15 duplication involving CHRNA7
49. The Hao-Fountain syndrome protein USP7 regulates neuronal connectivity in the brain via a novel p53-independent ubiquitin signaling pathway
50. Correction: PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial–mesenchymal transition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.